Group 1 - The MSCI Nordic countries index experienced a significant drop of 2.4% on February 24, closing at 383.03 points, marking the largest single-day decline since July 29, 2025 [1] - The healthcare sector led the decline, with Novo Nordisk's stock plummeting by 16.5%, making it the worst-performing stock in the Nordic region [1] - The sharp volatility in Novo Nordisk's stock is attributed to disappointing clinical data for its new weight-loss drug CagriSema, which achieved a 23% weight loss over 84 weeks but failed to meet its primary endpoint [1] Group 2 - Morgan Stanley characterized the clinical data results as the "worst-case scenario," while Jefferies highlighted the high dependency of Novo Nordisk's valuation on amycretin, indicating increased commercialization uncertainty [2] - JPMorgan noted that the results confirm Eli Lilly's Zepbound as the clear market leader, which is expected to continue gaining market share [2] - The setback for CagriSema has caused a ripple effect on the European weight-loss drug and GLP-1 sectors, with other companies like Zealand Pharma and Bachem experiencing declines [2] Group 3 - The competitive landscape in the global weight-loss drug market is rapidly differentiating, with Eli Lilly's Zepbound projected to generate $4.2 billion in revenue by Q4 2025, reflecting a 122% year-over-year increase [2] - Eli Lilly has also introduced a new formulation of Zepbound, consolidating a month's dosage into a single injection pen, which has received FDA approval for label expansion [2] - According to Dongfang Securities, Eli Lilly's tirzepatide is expected to achieve sales of $36.507 billion in 2025, while Novo Nordisk's semaglutide is projected to reach approximately $34.606 billion, ranking second [3]

Core Insights - Zealand Pharma experienced significant growth in 2025, highlighted by a transformative partnership with Roche for petrelintide and strong clinical advancements, setting the stage for a pivotal 2026 [1][2] Financial Performance - Revenue for FY 2025 reached DKK 9,215 million, a substantial increase from DKK 63 million in FY 2024 [3] - Net operating expenses, excluding other operating items, were DKK -2,101 million, compared to DKK -1,324 million in FY 2024 [3] - The operating result improved to DKK 6,959 million from a loss of DKK -1,272 million in FY 2024 [3] - Cash position at the end of FY 2025 was DKK 15,109 million, up from DKK 9,022 million in FY 2024 [4] 2026 Financial Guidance - Expected net operating expenses for 2026 are projected to be between DKK 2,700 million and DKK 3,300 million, primarily driven by research and development activities [5][7] - Zealand Pharma is eligible for potential milestone payments from Roche totaling USD 700 million, including a development milestone of USD 575 million and an anniversary payment of USD 125 million [8] Strategic Developments - Zealand Pharma aims to establish a leading amylin-based franchise around petrelintide, with plans for a Phase 3 program initiation in H2 2026 [5][10] - The company outlined its ambitious Metabolic Frontier 2030 strategy, targeting five product launches and over 10 clinical pipeline programs by 2030 [5] - A new research site in Boston is planned to enhance drug discovery capabilities, integrating AI-driven approaches with over 25 years of peptide expertise [5][15] Clinical Pipeline and Milestones - Phase 2 data from the ZUPREME-1 trial for petrelintide is expected to be reported imminently, with Phase 3 development anticipated to begin soon after [2][10] - Survodutide's Phase 3 data from the SYNCHRONIZETM program is also expected to be reported throughout 2026, potentially leading to regulatory submissions [2][10] Organizational Growth - Zealand Pharma saw a 41% increase in employee count in 2025, with an improved employee engagement score of 8.9 out of 10 and a low turnover rate of 7.8% [15]

Zealand Pharma Conference Call Summary Company Overview - **Company**: Zealand Pharma - **Industry**: Biotech, focusing on metabolic health and obesity treatment Core Points and Arguments - Zealand Pharma launched its **Metabolic Frontier 2030 strategy**, aiming to tackle the obesity pandemic and its related diseases, marking a pivotal year in the company's history [2][3] - The company aims to become a leading biotech in metabolic health, with ambitions to launch significant new medicines, including **Survodutide** (in partnership with Boehringer Ingelheim) and **Petrelintide** (in partnership with Roche) [3][4] - Zealand has a competitive advantage due to its 25 years of experience in metabolic health and peptides, combined with proprietary data that can enhance AI and machine learning capabilities in drug development [5][6] - The company has a strong financial position with over **DKK 2.5 billion** in cash and near-term milestones exceeding **$1.2 billion**, allowing it to fund its journey towards profitability [6] Pipeline and Clinical Development - Zealand expects multiple clinical data readouts in the coming year, including **Petrelintide phase 2 data** and **Survodutide phase 3 studies** [7][8] - The company anticipates launching five new products over the next five years, targeting obesity and rare diseases like congenital hyperinsulinism and short bowel syndrome [10] - Petrelintide aims to provide a weight loss of **15%-20%**, which aligns with patient expectations and offers a more tolerable weight loss experience compared to existing therapies [20][21] Market Dynamics and Challenges - The obesity pandemic is described as a significant healthcare challenge, with over **5 million deaths** attributed to obesity, highlighting the urgency for effective treatments [11] - Current GLP-1 therapies have a low adherence rate, with only **2%-4%** of the U.S. population on treatment, primarily due to side effects and cost [12][15] - Zealand emphasizes the need for innovative solutions that not only promote weight loss but also ensure long-term adherence to treatment [15][16] Partnerships and Collaborations - Zealand's partnership with Roche for Petrelintide is characterized as a strong collaboration, with a **50/50 profit share** and Roche handling manufacturing investments [22][23] - The partnership with Boehringer Ingelheim focuses on Survodutide, which is expected to lead in the GLP-1 space and has the potential to address conditions like MASH (metabolic dysfunction-associated steatotic liver disease) [24][25] Research and Development Investment - Zealand plans to invest **DKK 5 billion** in research over the next five years, significantly increasing its commitment to building a valuable metabolic health pipeline [29] - The company is exploring additional partnerships to enhance its pipeline and aims to develop **10 clinical candidates** within the next five years [30] Future Outlook - Zealand Pharma is positioned for a transformational year with significant clinical data readouts and a focus on addressing the obesity crisis through innovative therapies [30] - The company is committed to developing alternatives to GLP-1s, emphasizing the importance of patient experience and adherence in chronic disease management [50][52] Additional Insights - Zealand acknowledges the need for a shift in how obesity treatments are perceived, moving from a focus on weight loss numbers to the overall patient experience and long-term health benefits [31][32] - The company is also considering the development of a once-monthly Amylin therapy and oral small molecules, indicating a commitment to expanding treatment options in the obesity market [51][52]

Core Viewpoint - Zealand Pharma is seeking partners for innovative weight loss treatments that target the brain directly, emphasizing the central nervous system's role in metabolic regulation and immune response [4][6]. Group 1: Strategic Collaborations - Zealand Pharma is exploring collaborations to develop therapies that can cross the blood-brain barrier, with a focus on "shuttle technology" to safely deliver drugs to the brain [4][6]. - The company has engaged in discussions with Roche and other institutions regarding brain-targeted research, acknowledging the high difficulty of these projects but recognizing their potential to fundamentally change metabolic disease treatment [6]. - Zealand recently announced a $20 million upfront payment to OTR Therapeutics, with a total potential of $30 million, to leverage its oral small molecule platform for discovering new metabolic disease therapies [8]. Group 2: Product Pipeline and Development - Zealand's pipeline includes the promising drug petrelintide, which is expected to show an average weight loss of 8.6% over 16 weeks in its Phase II trial, with results anticipated in mid-2026 [9]. - The company is also advancing the dual agonist survodutide in Phase III trials for obesity and MASH, alongside other projects targeting short bowel syndrome and congenital hyperinsulinemia [9]. - Zealand's strategy includes a roadmap titled "Metabolic Frontier 2030," aiming to launch five products by 2030, indicating a long-term vision for growth in the metabolic disease sector [9]. Group 3: Market Position and Future Outlook - Zealand's entry into oral small molecule collaborations is seen as a risk mitigation strategy amid rising competition in the oral weight loss drug market, particularly with Novo Nordisk's oral semaglutide awaiting regulatory approval [8]. - The company believes it has sufficient research capabilities and financial reserves to navigate uncertainties in the market, positioning itself for continuous iteration and improvement [9]. - Zealand's future innovations may include improving insulin sensitivity unrelated to weight and eventually directly modulating brain receptors, showcasing a commitment to long-term health impact [10].

Core Viewpoint - Zealand Pharma is seeking partners for innovative weight loss treatments that target the brain directly, emphasizing the central nervous system's role in metabolic regulation and immune response [4][6]. Group 1: Strategic Collaborations - Zealand is exploring collaborations to develop therapies that can cross the blood-brain barrier, with a focus on "shuttle technology" to safely deliver drugs to the brain [4][6]. - The company has engaged in discussions with Roche and other institutions regarding brain-targeted research, acknowledging the high difficulty of these projects but recognizing their potential to fundamentally change metabolic disease treatment [6]. - Zealand has entered a partnership with OTR Therapeutics, paying a $20 million upfront fee, potentially reaching $30 million, to leverage OTR's oral small molecule platform for new metabolic disease therapies [8]. Group 2: Product Pipeline and Development - Zealand's pipeline includes the promising drug petrelintide, which is expected to show an average weight loss of 8.6% over 16 weeks in its Phase II trial, with results anticipated in mid-2026 [9]. - The company is also advancing the dual agonist survodutide in Phase III trials for obesity and MASH, alongside other candidates targeting short bowel syndrome and congenital hyperinsulinism [9]. - Zealand's strategy includes a roadmap titled "Metabolic Frontier 2030," aiming to launch five products by 2030, indicating a long-term vision for growth in the metabolic disease sector [9]. Group 3: Market Position and Future Outlook - Zealand is aware of the competitive landscape in oral weight loss medications, particularly with Novo Nordisk's oral semaglutide awaiting regulatory approval, and is cautious about committing to outcomes without believing in their potential [8]. - The company has a robust research capability and financial reserves, allowing it to navigate uncertainties in the market while continuing to innovate [9]. - Zealand's future innovations may include improving insulin sensitivity unrelated to weight and directly modulating brain receptors, showcasing a commitment to long-term health impacts [10].

Zealand Pharma Capital Markets Day Summary Company Overview - **Company**: Zealand Pharma - **Event**: 2025 Capital Markets Day - **Date**: December 11, 2025 - **Focus**: Management of obesity and metabolic health pipeline Key Industry Insights - **Obesity Market Evolution**: The obesity market has significantly evolved, with key trends reinforcing Zealand Pharma's perspectives shared two years ago [2][12] - **Healthcare Crisis**: Over 1 billion people globally are living with obesity, creating a civilization-scale problem that requires innovative solutions beyond current GLP-1-based therapies [14][15] - **Consumer Engagement**: The consumer segment is rapidly growing, with nearly two-thirds of discussions initiated by consumers, indicating a shift towards consumer-driven treatment choices [40][41] Core Company Strategies - **Pipeline Development**: Zealand Pharma aims to maximize the value of petrelintide, an amylin analog, and invest significantly in its metabolic health pipeline, increasing research investments fivefold over the next five years [22][24] - **Partnership with Roche**: A 50/50 partnership with Roche is established to co-commercialize petrelintide, combining Zealand's biotech agility with Roche's pharmaceutical strength [18][19] - **Research Expansion**: A new research hub in Boston will complement the existing Copenhagen site, focusing on AI, machine learning, and novel chemistry approaches [22][23] Product Highlights - **Petrelintide**: Described as the "crown jewel," petrelintide is designed to help individuals feel full faster and is positioned as a foundational therapy for weight management [7][17] - **Survodutide**: A dual agonist targeting GLP-1 and glucagon receptors, showing promising phase two data for weight loss and metabolic health improvements [50][56] Clinical Insights - **Weight Maintenance Focus**: Emphasis on transitioning from weight loss to weight maintenance, addressing the need for durable therapies that help maintain weight loss [16][34] - **Real-World Data**: High discontinuation rates of current therapies highlight the need for better patient experiences and alternatives to GLP-1 therapies, which often lead to gastrointestinal side effects [44][46] Future Outlook - **2030 Ambition**: Zealand Pharma's "Metabolic Frontier" ambition includes five product launches and over ten clinical candidates by 2030, aiming to establish itself as a generational biotech company [22][24] - **Transformational Potential**: The partnership with Roche and the development of innovative therapies position Zealand Pharma to redefine obesity management and address significant unmet medical needs [18][19][22] Additional Considerations - **Cultural Commitment**: Zealand Pharma emphasizes its unique culture and commitment to agility and innovation, which are seen as critical to its success in the competitive biotech landscape [11][25] - **Healthcare System Impact**: The company recognizes the broader societal implications of obesity and the need for comprehensive solutions that address the healthcare crisis associated with it [15][12]

Zealand Pharma's Strategic Vision - Zealand Pharma aims to redefine obesity care and build a generational biotech company in metabolic health[7, 18] - The company plans to launch 5 products in 5 years and have 10+ clinical programs in metabolic health by 2030[19] - Key catalysts include Survodutide Phase 3 obesity data in 2029/2030 and Petrelintide Phase 2 data and Phase 3 initiation[20] Addressing Obesity and Metabolic Health - Over 1 billion people are living with obesity today, requiring a civilization-scale health shift[9] - The GLP-1 revolution has changed expectations, proving obesity is drug treatable and resetting expectations for patients, systems, and markets[10, 11] - By 2030, an estimated 50% of adults globally are expected to live with overweight or obesity[40] - Only ~3% of eligible people in the U S are treated with GLP-1s, and ~12% of Americans have been exposed to GLP-1s[45] Survodutide's Potential - Survodutide, a glucagon/GLP-1 dual agonist, offers coordinated regulation of energy expenditure and energy intake[100] - In a Phase 2 trial, Survodutide dose-dependently reduced body weight by up to 18 7% in 46 weeks[106] - Survodutide also demonstrated breakthrough liver fibrosis improvement in MASH in a Phase 2 trial[128] Petrelintide as a Foundational Therapy - Petrelintide, a long-acting amylin analog, is designed for high-quality, durable weight loss and can be used stand-alone or in combination with CT-388 (GLP-1/GIP)[13] - Petrelintide holds the potential to deliver ~15–20% weight loss with a benign tolerability profile[231] - A Phase 2 trial with Petrelintide/CT-388 is planned for initiation in H1 2026[240]

Core Insights - Zealand Pharma has announced a five-year strategy called "Metabolic Frontier 2030" to enhance its anti-obesity portfolio amid increasing competition in the market [2][3] - The company aims for five drug launches, at least ten clinical pipeline programs, and industry-leading cycle times by 2030 [2] - Zealand's shares have dropped 29% year-to-date, reflecting investor concerns about market fragmentation and competition [2] Company Strategy - The strategy will leverage strategic partnerships, accelerated drug development, and expanded research capabilities to create a valuable metabolic health pipeline [3] - Zealand Pharma is focusing on candidates with greater potential for clinical differentiation, having paused development of a dual agonist due to market saturation [8] Drug Development - One of Zealand's promising drugs, petrelintide, targets the pancreatic amylin hormone and has shown moderate side effects in early-stage trials [4] - Mid-stage data for petrelintide is expected early next year, while data for its dual GLP-1 agonist, survodutide, will be available throughout 2026 [4] Market Dynamics - Novo Nordisk and Eli Lilly currently dominate the weight loss drug market, with analysts predicting the market could reach $150 billion annually by the start of the next decade [5] - Eli Lilly has gained investor favor due to its effective weight loss drugs and diverse portfolio, while Novo Nordisk is experiencing significant stock declines [6][7] Competitive Landscape - Big Pharma companies like AstraZeneca, Amgen, and Pfizer are also entering the obesity drug market, aiming to capture market share from Lilly and Novo [9] - Analysts believe that while Lilly may hold over 50% of the global market share, this will stabilize as competitors launch next-generation drugs [10] Partnerships and Research - Zealand Pharma has entered an agreement with OTR Therapeutics to develop oral small molecule treatments for metabolic diseases, involving an upfront payment of $20 million and potential milestones worth up to $2.5 billion [11] - The company plans to open a new research site in Boston, combining its peptide drug expertise with AI-driven drug discovery [12]

Core Viewpoint - Novo Nordisk has faced its worst performance year ever due to poor clinical trial results, multiple profit warnings, and intense market competition, leading to a stock price drop of over 50% in 2023, erasing gains since the approval of Wegovy in 2021 [1][3]. Group 1: Financial Performance - The stock price of Novo Nordisk has fallen more than 50% this year, nearly negating the significant increase since Wegovy's approval for weight loss treatment in 2021 [1]. - Analysts predict that Novo Nordisk's sales may decline by 2026, contrasting sharply with the previous growth rates of 25%-30% during its prosperous period [3]. - The current trading price of the stock is approximately 14 times expected earnings, which is half of the average valuation over the past five years and over 10% cheaper than the MSCI World Pharmaceuticals Index [3][10]. Group 2: Competitive Landscape - The main threat to Novo Nordisk comes from Eli Lilly, whose stock has surged over 28% this year, contrasting with Novo Nordisk's decline [4]. - Novo Nordisk's weight loss drugs are reportedly less effective than those from Eli Lilly, which has enhanced Eli Lilly's market communication capabilities [7]. - The market sentiment has shifted, with investors favoring Eli Lilly as the primary beneficiary of the significant growth in the market, indicating a strong preference for Eli Lilly over Novo Nordisk [7]. Group 3: Future Prospects - Novo Nordisk is banking on new product launches to recover from its current challenges, including a more potent version of Wegovy and an oral version expected to launch early next year [8]. - The new CEO, Mike Doustdar, has indicated that the company has "sufficient" pills for targeted release and is in preliminary talks with Hims & Hers Health Inc. for remote sales of obesity pills [8]. - Analysts remain optimistic about Novo Nordisk, with 17 out of 33 institutions maintaining a buy rating, suggesting that the stock price drop may have been overdone and that a higher valuation is justified based on the company's strong R&D track record [10].

Core Viewpoint - Danish biotech Zealand Pharma is accelerating the development and expanding research of its experimental obesity drug candidates to differentiate them in a competitive market [1] Company Summary - Zealand Pharma aims to enhance its position in the obesity treatment sector by speeding up the development of its drug candidates [1] - The company is focusing on research expansion to create unique offerings in the obesity drug market [1] Industry Summary - The obesity drug market is becoming increasingly competitive, prompting companies like Zealand Pharma to innovate and differentiate their products [1]